ASCAL 100 Milligram Tablets Effervescent Ireland - English - HPRA (Health Products Regulatory Authority)

ascal 100 milligram tablets effervescent

meda health sales ireland limited - carbasalate calcium - tablets effervescent - 100 milligram

COMPETACT 15 MG  850 MG Israel - English - Ministry of Health

competact 15 mg 850 mg

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - film coated tablets - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

SERENACE haloperidol 5.0 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

serenace haloperidol 5.0 mg tablet bottle

aspen pharmacare australia pty ltd - haloperidol, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; calcium hydrogen phosphate dihydrate; brilliant scarlet 4r - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

SERENACE haloperidol 0.5 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

serenace haloperidol 0.5 mg tablet bottle

aspen pharmacare australia pty ltd - haloperidol, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; quinoline yellow; calcium hydrogen phosphate dihydrate; green s - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

SERENACE haloperidol 1.5 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

serenace haloperidol 1.5 mg tablet bottle

aspen pharmacare australia pty ltd - haloperidol, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; acacia; magnesium stearate; calcium hydrogen phosphate dihydrate - chronic therapy: the management of manifestations of psychotic disorders such as schizophrenia, psychosis due to organic brain damage or mental deficiency, the manic phase of manic depressive illness, gilles de la tourette syndrome. short term therapy: the treatment of acute alcoholism for the relief of delusions, hallucinations and confused states, and for the control of accompanying tremulousness and aggressive behaviour. in the treatment of intractable nausea and vomiting associated with radiation or malignancy and not responding to other therapy. neuroleptanalgesia

Vidalta 10 mg prolonged-release tablets for cats Ireland - English - HPRA (Health Products Regulatory Authority)

vidalta 10 mg prolonged-release tablets for cats

intervet ireland limited - carbimazole - tablet - 10 mg/tablet - carbimazole - cats - hormone

Vidalta 15 mg prolonged-release tablets for cats Ireland - English - HPRA (Health Products Regulatory Authority)

vidalta 15 mg prolonged-release tablets for cats

intervet ireland limited - carbimazole - tablet - 15 mg/tablet - carbimazole - cats - hormone

ODEFSEY emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet Australia - English - Department of Health (Therapeutic Goods Administration)

odefsey emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir alafenamide fumarate, quantity: 28.04 mg; rilpivirine hydrochloride, quantity: 27.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; croscarmellose sodium; polysorbate 20; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - odefsey is indicated as a complete regimen for the treatment of hiv-1 infection in adults and adolescents (12 years and older with body weight at least 35 kg) with plasma hiv-1 rna <= 100,000 copies/ml at the start of therapy. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of odefsey.

APO-OMEPRAZOLE omeprazole 20 mg enteric-coated tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-omeprazole omeprazole 20 mg enteric-coated tablet blister pack

arrotex pharmaceuticals pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide black; microcrystalline cellulose; povidone; iron oxide red; crospovidone; purified talc; lactose monohydrate; hypromellose phthalate; magnesium stearate; triacetin; ascorbyl palmitate - omeprazole tablets are indicated for: a. gastro-oesophageal reflux disease (gord): 1. symptomatic gord: the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis: the treatment and prevention of relapse. b. peptic ulcers: 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with heliobacter pylori infection. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. c. zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome.

METEX XR metformin hydrochloride 500 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

metex xr metformin hydrochloride 500 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; povidone; hypromellose - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.